Regarding: Increased fracture risk after discontinuation of anti‐osteoporosis medications among hip fracture patients

Abstract

We have carefully read the cohort study by Fu et al. on anti-osteoporosis medication (AOM) [1]. The authors reported that persistent anti-osteoporosis drug users have a lower risk of major fractures compared with patients who discontinued the treatment. The strengths of the study are its size and follow-up period from analyzing Taiwan's nationwide database (National Health Insurance Research Database [NHIRD]), which includes 99% of Taiwan's population.

Authors' reply: Increased fracture risk after discontinuation of anti‐osteoporosis medications among hip fracture patients

“…We are thankful to Wei et al. for the comments proposing a number of subgroup analyses of our data [1]. While these subgroup analyses are clinically meaningful and biologically plausibile, the data currently available are not large enough for the sex‐specific analyses or for limiting the male patients to those treated after 2014 when the reimbursement policy for denosumab (DMAB) was updated.…”